Verified ComparisonLast updated: 27 March 2026
Larazotide vs BPC-157
Larazotide (tight-junction stabilizer) is designed for celiac-disease intestinal permeability. BPC-157 is a broad-spectrum recovery peptide.
Larazotide
Immune
3.9/ 5
B+
BPC-157
Recovery
4.5/ 5
A
Editor's note
Larazotide targets tight junctions; BPC-157 offers broader tissue-healing scope.
| Criterion | Larazotide | BPC-157 |
|---|---|---|
| Primary target | Intestinal tight junctions | Tissue healing (broad) |
| Celiac-disease focus | Primary | Secondary |
| Preclinical scope | GI-focused | Multi-tissue |
| Clinical trial data | Celiac trials conducted | Limited human data |
| Regulatory approval (AU) | Investigational | Not approved |
Frequently asked questions
Larazotide for celiac/tight-junction pathology; BPC-157 for broader healing.
Want to read the full reviews?